Citations

Clear

3314 citation(s) found for "Yu, Alexander".

How Do the Outcomes of Radiation-Associated Pelvic and Sacral Bone Sarcomas Compare to Primary Osteosarcomas following Surgical Resection?
Lazarides, Alexander L. , Gundavda, Manit K. , Novak, Rostislav , Ghert, Michelle , Wilson, David , Rose, Peter S. , Wong, Philip , Houdek, Matthew T. , Tsoi, Kim M., Ghert, Michelle , Wong, Philip , Houdek, Matthew T , Tsoi, Kim M , Burke, Zachary D. C. , Griffin, Anthony M. , Ferguson, Peter C. , Wunder, Jay S.

Mayo Clinic

Cancers | April 27, 2022 | Volume: 14 | Issue: 9 | Pages: 2179

10.3390/cancers14092179 | PMID 35565308 Get It

Radiation-associated sarcoma of the pelvis and/or sacrum (RASB) is a rare but challenging disease process associated with a poor prognosis. We hypothesized that patients with RASB would have worse surgical and oncologic outcomes than patients diagnosed with primary pelvic or sacral bone sarcomas. This was a retrospective, multi-institution, comparative analysis. We reviewed surgically treated patients from multiple tertiary care centers who were diagnosed with a localized RASB. We also identified a comparison group including all patients diagnosed with a primary localized pelvic or sacral osteosarcoma/spindle cell sarcoma of bone (POPS). There were 35 patients with localized RASB and 73 patients with POPS treated with surgical resection. Patients with RASB were older than those with POPS (57 years vs. 38 years, p < 0.001). Patients with RASB were less likely to receive chemotherapy (71% for RASB vs. 90% for POPS, p = 0.01). Seventeen percent of patients with RASB died in the perioperative period (within 90 days of surgery) as compared to 4% with POPS (p = 0.03). Five-year disease-specific survival (DSS) (31% vs. 54% p = 0.02) was worse for patients with RASB vs. POPS. There was no difference in 5-year local recurrence free survival (LRFS) or metastasis free survival (MFS). RASB and POPS present challenging disease processes with poor oncologic outcomes. Rates of perioperative mortality and 5-year DSS are worse for RASB when compared to POPS.
New Methodology for Accurate Determination of Molecular Co-localization at the Nanoscale
Verkhoturov, Dmitriy S., Eller, Michael J. , Han, Yong Duk, Верхотуров, С. В., Revzin, Alexander , Eller, Michael J , Schweikert, Emile A , Crulhas, Bruno P.

Mayo Clinic

Langmuir | April 25, 2022 | Volume: 38 | Issue: 18 | Pages: 5626-5632

10.1021/acs.langmuir.2c00217 | PMID 35465673 Get It

Acute Leukemia Classification Using Transcriptional Profiles From Low-Cost Nanopore mRNA Sequencing
Wang, Jeremy , Bhakta, Nickhill , Miller, Vanessa Ayer , Revsine, Mahler, Litzow, Mark R. , Paietta, Elisabeth, Fedoriw, Yuri, Roberts, Kathryn G., Gu, Zhaohui , Mullighan, Charles G. , Jones, Corbin D. , Ayer Miller, Vanessa , Alexander, Thomas B , Mullighan, Charles G , Wang, Jeremy R , Bhakta, Nickhill , Revsine, Mahler, Litzow, Mark R. , Paietta, Elisabeth, Fedoriw, Yuri, Roberts, Kathryn G., Gu, Zhaohui , Jones, Corbin D.

Mayo Clinic

JCO Precision Oncology | April 20, 2022 | Volume: No volume available | Issue: 6 | Pages: No page available

10.1200/po.21.00326 | PMID 35442720 Get It

PURPOSE Most cases of pediatric acute leukemia occur in low- and middle-income countries, where health centers lack the tools required for accurate diagnosis and disease classification. Recent research shows the robustness of using unbiased short-read RNA sequencing to classify genomic subtypes of acute leukemia. Compared with short-read sequencing, nanopore sequencing has low capital and consumable costs, making it suitable for use in locations with limited health infrastructure. MATERIALS AND METHODS We show the feasibility of nanopore mRNA sequencing on 134 cryopreserved acute leukemia specimens (26 acute myeloid leukemia [AML], 73 B-lineage acute lymphoblastic leukemia [B-ALL], 34 T-lineage acute lymphoblastic leukemia, and one acute undifferentiated leukemia). Using multiple library preparation approaches, we generated long-read transcripts for each sample. We developed a novel composite classification approach to predict acute leukemia lineage and major B-ALL and AML molecular subtypes directly from gene expression profiles. RESULTS We demonstrate accurate classification of acute leukemia samples into AML, B-ALL, or T-lineage acute lymphoblastic leukemia (96.2% of cases are classifiable with a probability of > 0.8, with 100% accuracy) and further classification into clinically actionable genomic subtypes using shallow RNA nanopore sequencing, with 96.2% accuracy for major AML subtypes and 94.1% accuracy for major B-lineage acute lymphoblastic leukemia subtypes. CONCLUSION Transcriptional profiling of acute leukemia samples using nanopore technology for diagnostic classification is feasible and accurate, which has the potential to improve the accuracy of cancer diagnosis in low-resource settings.
Traumatic cervical spine distraction injury
Robinson, Kristin A. , Jorgensen, Scott A., Towbin, Richard B. , Towbin, Alexander J.

Mayo Clinic

Applied Radiology | April 20, 2022 | Volume: No volume available | Issue: No issue available | Pages: 28-30

10.37549/ar2191 Get It

A prescription for an outpatient parenteral antimicrobial therapy ( OPAT ) rotation for pharmacy residents
Alexander, Bryan , Rivera, Christina G. , Childs‐Kean, Lindsey M. , Rivera, Christina G , Mahoney, Monica V. , Ryan, Keenan

Mayo Clinic

JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY | April 19, 2022 | Volume: 4 | Issue: 2 | Pages: 234-244

10.1002/jac5.1377 Get It

Abstract Background Outpatient parenteral antimicrobial therapy (OPAT) is an emerging area for pharmacist involvement. However, many residency training programs do not offer OPAT rotation opportunities for their residents. Objective To provide a blueprint for residency programs hoping to offer OPAT rotations for postgraduate year 1 (PGY1) or postgraduate year 2 (PGY2) pharmacy residents. Results As a rotation area with copious patient interaction, there are many unique accreditation objectives that can be taught and evaluated in an OPAT rotation. The OPAT rotation format may be longitudinal or block. Activities the resident can complete include predischarge evaluation, patient counseling, medication selection, physical examinations, laboratory monitoring, patient presentations, documentation, projects, and educational presentations. Conclusion OPAT rotations provide many opportunities for residents to satisfy the objectives required in residency training.
Racial and ethnic disparities in early treatment with immunotherapy for advanced HCC in the United States
Ahn, Joseph , Lauzon, Marie , Luu, Michael , Noureddin, Mazen , Ayoub, Walid S. , Kuo, Alexander , Sundaram, Vinay , Kosari, Kambiz , Nissen, Nicholas N. , Hendifar, Andrew , Roberts, Lewis R. , Yang, Ju Dong , Ahn, Joseph C , Singal, Amit , Yang, Ju Dong , Roberts, Lewis R , Gong, Jun , Abou‐Alfa, Ghassan K. , Singal, Amit G.

Mayo Clinic

Hepatology | April 16, 2022 | Volume: 76 | Issue: 6 | Pages: 1649-1659

10.1002/hep.32527 | PMID 35429171 Get It

Abstract Background and Aims Immunotherapy has emerged as an effective treatment for patients with advanced‐stage HCC. We aimed to investigate the efficacy of immunotherapy for advanced HCC in a nationwide cohort and racial and ethnic disparities in access to immunotherapy. Approach and Results We used the US National Cancer Database to identify patients with tumor‐node‐metastasis stage 3 or 4 HCC between 2017 and 2018. We performed multivariable Cox regression to identify factors associated with overall survival (OS) and logistic regression to identify factors associated with receipt of immunotherapy. Of the 3,990 patients treated for advanced HCC, 3,248 (81.4%) patients received chemotherapy and 742 (18.6%) patients received immunotherapy as a first‐line treatment. Immunotherapy was associated with improved OS compared with chemotherapy (adjusted HR: 0.76, 95% CI: 0.65–0.88) after adjusting for covariates. There were racial and ethnic disparities in access to immunotherapy, with Hispanic (adjusted OR [aOR]: 0.63, 95% CI: 0.46–0.83) and Black patients (aOR: 0.71, 95% CI: 0.54–0.89) less likely to receive immunotherapy compared with White patients. There was a significant interaction between race‐ethnicity and facility type, with higher disparity observed in nonacademic centers (interaction p = 0.004). Conclusions Immunotherapy was associated with improved OS compared with chemotherapy in advanced HCC. There are significant disparities in early access to immunotherapy, likely due to differential access to clinical trials and experimental therapies. A comprehensive approach to monitoring and eliminating racial‐ethnic disparities in the management of advanced HCC is urgently needed.
Complications and outcomes of posterior fossa decompression with duraplasty versus without duraplasty for pediatric patients with Chiari malformation type I and syringomyelia: a study from the Park-Reeves Syringomyelia Research Consortium
Akbari, S. Hassan A. , Ackerman, Laurie L. , Adelson, P. David , Albert, Gregory W. , Aldana, Philipp R. , Alden, Tord D. , Anderson, Richard C. E. , Bauer, David F. , Bethel-Anderson, Tammy, Bierbrauer, Karin S. , Brockmeyer, Douglas L. , Chern, Joshua J. , Couture, Daniel E., Durham, Susan, Ellenbogen, Richard G. , Eskandari, Ramin , Fuchs, Herbert E., Greene, Stephanie , Gross, Naina L. , Guillaume, Daniel, Hankinson, Todd C. , Heuer, Gregory G. , Iantosca, Mark, Iskandar, Bermans J. , Jackson, Eric M. , Kaufman, Bruce A., Keating, Robert F., Khan, Nicklaus R., Krieger, Mark D., Leonard, Jeffrey R. , Maher, Cormac O. , Mangano, Francesco T. , McComb, J. Gordon , McEvoy, Sean D., Meehan, Thanda, Muhlbauer, Michael S., O’Neill, Brent R., Olavarria, Greg, Ragheb, John , Shannon, Chevis N. , Stone, Scellig , Strahle, Jennifer M. , Tamber, Mandeep S. , Torner, James C., Tuite, Gerald F. , Tyler‐Kabara, Elizabeth C. , Wait, Scott D. , Wellons, John C. , Whitehead, William E. , Limbrick, David D. , Torner, James C. , Yahanda, Alexander T. , Ahmed, Raheel , Daniels, David J. , Dlouhy, Brian J , Grant, Gerald A. , Graupman, Patrick C. , Greenfield, Jeffrey P. , Guillaume, Daniel J., Jallo, George I. , Johnston, James M. , Menezes, Arnold H. , Selden, Nathan R. W. , Shah, Manish N. , Shimony, Joshua S. , Park, Tae Sung , Limbrick, David D.

Mayo Clinic

Journal of Neurosurgery: Pediatrics | April 15, 2022 | Volume: 30 | Issue: 1 | Pages: 39-51

10.3171/2022.2.peds21446 | PMID 35426814 Get It

OBJECTIVE The aim of this study was to determine differences in complications and outcomes between posterior fossa decompression with duraplasty (PFDD) and without duraplasty (PFD) for the treatment of pediatric Chiari malformation type I (CM1) and syringomyelia (SM). METHODS The authors used retrospective and prospective components of the Park-Reeves Syringomyelia Research Consortium database to identify pediatric patients with CM1-SM who received PFD or PFDD and had at least 1 year of follow-up data. Preoperative, treatment, and postoperative characteristics were recorded and compared between groups. RESULTS A total of 692 patients met the inclusion criteria for this database study. PFD was performed in 117 (16.9%) and PFDD in 575 (83.1%) patients. The mean age at surgery was 9.86 years, and the mean follow-up time was 2.73 years. There were no significant differences in presenting signs or symptoms between groups, although the preoperative syrinx size was smaller in the PFD group. The PFD group had a shorter mean operating room time (p < 0.0001), fewer patients with > 50 mL of blood loss (p = 0.04), and shorter hospital stays (p = 0.0001). There were 4 intraoperative complications, all within the PFDD group (0.7%, p > 0.99). Patients undergoing PFDD had a 6-month complication rate of 24.3%, compared with 13.7% in the PFD group (p = 0.01). There were no differences between groups for postoperative complications beyond 6 months (p = 0.33). PFD patients were more likely to require revision surgery (17.9% vs 8.3%, p = 0.002). PFDD was associated with greater improvements in headaches (89.6% vs 80.8%, p = 0.04) and back pain (86.5% vs 59.1%, p = 0.01). There were no differences between groups for improvement in neurological examination findings. PFDD was associated with greater reduction in anteroposterior syrinx size (43.7% vs 26.9%, p = 0.0001) and syrinx length (18.9% vs 5.6%, p = 0.04) compared with PFD. CONCLUSIONS PFD was associated with reduced operative time and blood loss, shorter hospital stays, and fewer postoperative complications within 6 months. However, PFDD was associated with better symptom improvement and reduction in syrinx size and lower rates of revision decompression. The two surgeries have low intraoperative complication rates and comparable complication rates beyond 6 months.
Efficacy and Safety of Twice-Daily versus Three-Times Daily Saquinavir Soft Gelatin Capsules as Part of Triple Combination Therapy for HIV-1 Infection
Wheat, L. Joseph , Farthing, Charles, Cohen, Calvin, Pierone, Gerald , Lalezari, Jay , Pilson, Robert S, Siemon-Hryczyk, Peggy, Appendix), for the TIDBID (NR15520/M61018) study team (members listed in, Baxter, John, Beer, Victor L., Bellos, Nicholas, Bissett, Jack, Braun, James, Brosgart, Carol, Burnside, Alfred F., Cervia, Joe, Cheeseman, Sarah H., Cimoch, Paul J., Cohen, Calvin, DeJesus, Edwin, Diaz, Leslie L, Dieterich, Douglas T. , Dobkin, Jay F., Dretler, Robin, El-Sadr, Waafa, Eng, Robert H.K., Feleke, Getachew, Fessel, Jeffrey , Fish, Douglas N. , Galpin, Jeffrey E., Gathe, Joseph, Gilson, Ian, Gold, Marla, Goodgame, Jeffrey, Greenberg, Richard N. , Greiger, Paola, Grossman, Howard, Grossman, Ron, Hanna, Barbara, Hathaway, Bruce, Hoffman-Terry, Margaret, Jacobson, Susan , Jemsek, Joseph G., Jordan, Wilbert, Kaplan, Mark, Kostman, Jay R., Landesman, Sheldon H., Lindquist, Craig, Madhava, Valsa, Marsh, Bryan J., Martin, Dean, Mathur‐Wagh, Usha, McMeeking, Alexander, Miao, Peter, Mogyoros, Miguel, Mustafa, Mahmoud M., Nadler, Jeffrey P., Norris, Dorece, Onbirbak, Brian, Parker, Richard H, Pearce, Daniel, Pierone, Gerald, Poblete, Ronald, Poretz, Donald M., Reyelt, M Christine, Rivera-Vazquez, Carlos, Salvato, Patricia, Sands, Michael, Schwartz, Robert A., Sension, Michael, Skowron, Gail, Slater, Leonard N., Stavola, Joseph, Steinhart, Corklin, Temesgen, Zelalem , Thompson, Melanie , Timpone, Joseph, Vollmer, Kelly, Wada, Suzanne, Wheat, L Joseph, Yangco, Bienvenido G., Carey, Peter, Jablonowski, H, Theisen, Albert, Ocana, Inma, Appendix), for the TIDBID (NR15520/M61018) study team (members listed in, Burman, William J. , Cohen, Calvin, Feinberg, Judith , Goodrich, James , Jacobson, Susan, Kaplan, Mark, Lalezari, Jacob , MacArthur, Rodger D. , Murphy, Robert L. , Mustafa, Mahmoud, Pierone, Gerald, Reyelt, M. Christine, Smith, David C. , Valentine, Fred T. , Ward, Douglas, Wheat, L Joseph, Carey, Peter, Lazzarin, Adriano , Ocana, Inma

Mayo Clinic

Antiviral Therapy | April 14, 2022 | Volume: 7 | Issue: 3 | Pages: 199-209

10.1177/135965350200700310 Get It

Objective The objective of this study was to determine whether a triple therapy regimen incorporating twice-daily saquinavir is as effective as a three-times daily regimen. Methods This was an open-label, Phase III, multicentre, 48-week study involving 837 HIV-1-infected patients randomised to one of the following: saquinavir soft gel capsule (SGC) 1200 mg three-times daily, plus two nucleoside reverse transcriptase inhibitors (NRTIs) (arm A); saquinavir SGC 1600 mg twice-daily, plus two NRTIs (arm B); saquinavir SGC 1200 mg twice-daily and nelfinavir 1250 mg twice-daily, plus a single NRTI (arm C). The primary outcome measure was the virological response in arm A versus B and in arm A versus C with respect to the percentage of patients whose plasma HIV-1 RNA levels fell below the level of quantification for the Amplicor assay (<400 copies/ml) at weeks 24 and 48. Results At 48 weeks, the percentage of patients with plasma HIV-1 RNA levels <400 copies/ml was 47.1% (arm A), 45.3% (arm B) and 42.7% (arm C) in the intention-to-treat analysis. The treatment difference between arm B–arm A was -1.8% (95% confidence intervals -10.1, 6.5) and for arm C–arm A was -4.5% (95% confidence intervals -12.7, 3.7) in the intention-to-treat analysis. These differences fell within the maximum allowable difference (±12%) for arm B compared with arm A. At week 24, the percentage of patients with HIV-1 RNA levels <400 copies/ml was 59.6% (arm A), 57.6% (arm B) and 51.3% (arm C). Conclusions A twice-daily triple therapy regimen incorporating saquinavir SGC plus two NRTIs was of equivalent efficacy to the three-times daily regimen studied. All regimens were generally well tolerated.
Tissue donations for multiple sclerosis research: current state and suggestions for improvement
Vanderdonckt, Patrick, Comı, Gıancarlo , Bruyn, Alexander de , Huitinga, Inge , Kuhlmann, Tanja , Lucchinetti, Claudia F. , Metz, Imke , Reynolds, Richard , Metz, Imke , Reynolds, Richard , Aloisi, Francesca , Hartung, Hans‐Peter , Lassmann, Hans

Mayo Clinic

Brain Communications | April 14, 2022 | Volume: 4 | Issue: 2 | Pages: No page available

10.1093/braincomms/fcac094 | PMID 35480225 Get It

AbstractAlthough major progress in multiple sclerosis research has been made during the last decades, key questions related to the cause and the mechanisms of brain and spinal cord pathology remain unresolved. These cover a broad range of topics, including disease aetiology, antigenic triggers of the immune response inside and/or outside the CNS and mechanisms of inflammation, demyelination neurodegeneration and tissue repair. Most of these questions can be addressed with novel molecular technologies in the injured CNS. Access to brain and spinal cord tissue from multiple sclerosis patients is, therefore, of critical importance. High-quality tissue is provided in part by the existing brain banks. However, material from early and highly active disease stages is limited. An initiative, realized under the patronage of the European Charcot Foundation, gathered together experts from different disciplines to analyse the current state of multiple sclerosis tissues collected post-mortem or as biopsies. Here, we present an account of what material is currently available and where it can be accessed. We also provide recommendations on how tissue donation from patients in early disease stages could be potentially increased and for procedures of tissue sampling and preservation. We also suggest to create a registry of the available tissues that, depending on the source (autopsy versus biopsy), could be made accessible to clinicians and researchers.
Recommendations on the Appropriate Management of Steroids and Discharge Planning During and After Hospital Admission for Moderate-Severe Ulcerative Colitis: Results of a RAND Appropriateness Panel
Dulai, Parambir S. , Raffals, Laura E. , Kochhar, Gursimran , Damas, Oriana M. , Sauk, Jenny , Levy, Alexander N., Sofia, M. Anthony , Tuskey, Anne , Deepak, Parakkal , Yarur, Andrés , Afzali, Anita , Deepak, Parakkal , Yarur, Andres J , Rai, Victoria , Lukin, Dana J. , Hudesman, David , Ananthakrishnan, Ashwin N. , Cross, Raymond K. , Hanauer, Stephen B. , Siegel, Corey A

Mayo Clinic

American Journal of Gastroenterology | April 13, 2022 | Volume: 117 | Issue: 8 | Pages: 1288-1295

10.14309/ajg.0000000000001775 | PMID 35416799 Get It

INTRODUCTION: Limited guidance exists for the postdischarge care of patients with ulcerative colitis hospitalized for moderate-severe flares. METHODS: RAND methodology was used to establish appropriateness of inpatient and postdischarge steroid dosing, discharge criteria, follow-up, and postdischarge biologic or small molecule initiation. A literature review informed on the panel's voting, which occurred anonymously during 2 rounds before and after a moderated virtual session. RESULTS: Methylprednisolone 40–60 mg intravenous every 24 hours or hydrocortisone 100 mg intravenous 3 times daily is appropriate for inpatient management, with methylprednisolone 40 mg being appropriate if intolerant of higher doses. It is appropriate to discharge patients once rectal bleeding has resolved (Mayo subscore 0–1) and/or stool frequency has returned to baseline frequency and form (Mayo subscore 0–1). It is appropriate to discharge patients on 40 mg of prednisone after observing patients for 24 hours in hospital to ensure stability before discharge. For patients being discharged on steroids without in-hospital biologic or small molecule therapy initiation, it is appropriate to start antitumor necrosis factor (TNF) therapy after discharge for anti-TNF-naive patients. For anti-TNF-exposed patients, it is appropriate to start vedolizumab or ustekinumab for all patients and tofacitinib for those with a low risk of adverse events. It is appropriate to follow up patients clinically within 2 weeks and with lower endoscopy within 4–6 months after discharge. DISCUSSION: We provide recommendations on the inpatient and postdischarge management of patients with ulcerative colitis hospitalized for moderate-severe flares.